Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium

We investigated effectiveness of (1) mRNA booster vaccination versus primary vaccination only and (2) heterologous (viral vector–mRNA) versus homologous (mRNA–mRNA) prime-boost vaccination against severe outcomes of BA.1, BA.2, BA.4 or BA.5 Omicron infection (confirmed by whole genome sequencing) among hospitalized COVID-19 patients using observational data from national COVID-19 registries. In addition, it was investigated whether the difference between the heterologous and homologous prime-boost vaccination was homogenous across Omicron sub-lineages. Regression standardization (parametric g-... Mehr ...

Verfasser: Marjan Meurisse
Lucy Catteau
Joris A. F. van Loenhout
Toon Braeye
Laurane De Mot
Ben Serrien
Koen Blot
Emilie Cauët
Herman Van Oyen
Lize Cuypers
COVID-19 Genomics Belgium Consortium
Annie Robert
Nina Van Goethem
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Reihe/Periodikum: Vaccines, Vol 11, Iss 2, p 378 (2023)
Verlag/Hrsg.: MDPI AG
Schlagwörter: COVID-19 vaccination / clinical severity / SARS-CoV-2 variants / Medicine / R
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28971705
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.3390/vaccines11020378